IL1B and chronic kidney disease: Following the significant CV risk reduction in CVD patients following interleukin (IL)-1β monoclonal antibody treatment, it is tempting to speculate whether CKD patients need additional specific anti-inflammatory interventions in order to further reduce their considerable residual CV risk.